D. Ross Camidge, University of Colorado Denver (IMAGE)

University of Colorado Anschutz

D. Ross Camidge, University of Colorado Denver

Caption

At ASCO 2015, Dr. Ross Camidge and colleagues report promising phase I/II clinical trial results of the drug brigatinib against ALK+ non-small cell lung cancer.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.